Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: A substudy of the ANRS 099 ALIZE trial

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 5, 2008, Pages 1122-1129

  Lafaurie, Matthieu ^a   Collin, Fidéline ^b   Bentata, Michele ^c   Garré, Michel ^d   Leport, Catherine ^e   Levy, Yves ^f,g   Goujard, Cécile ^h   Chêne, Geneviève ^b   Molina, Jean Michel ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c AVICENNE HOSPITAL   (France)

^d SERVICE DE RHUMATOLOGIE   (France)

^e BICHAT HOSPITAL   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^h BICÊTRE HOSPITAL   (France)

Author keywords

Bacterial infection; HAART; Haemoglobin; Neutrophil; Quality of life

Indexed keywords

DIDANOSINE; EFAVIRENZ; EMTRICITABINE; HEMOGLOBIN; HEMOPOIETIC GROWTH FACTOR; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; BACTERIAL INFECTION; BLOOD TOXICITY; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; NEUTROPHIL COUNT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE COUNT; VIRUS INHIBITION;

ADULT; ANTI-HIV AGENTS; BACTERIAL INFECTIONS; BENZOXAZINES; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DEOXYCYTIDINE; DIDANOSINE; FEMALE; HEMOGLOBINS; HIV INFECTIONS; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; PANCYTOPENIA; PLATELET COUNT; PREVALENCE; ZIDOVUDINE;

EID: 54549094981     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn309     Document Type: Article

References (28)

1. Volberding PA, Levine AM, Dieterich D et al. Anaemia in HIV infection: Clinical impact and evidence-based management strategies. Clin Infect Dis 2004; 38: 1454-63.
2. Belperio PS, Rhew DC. Prevalence and outcomes of anaemia in individuals with human immunodeficiency virus: A systematic review of the literature. Am J Med 2004; 116 Suppl 7A: 27-43S.
3. Sloand E. Haematologic complications of HIV infection. AIDS Rev 2005; 7: 187-96.
4. Zon L, Arkin C, Groopman J. Haematologic manifestations of the human immunodeficiency virus (HIV). Semin Haematol 1988; 25: 208-19.
5. Berhane K, Karim R, Cohen M et al. Impact of highly active antiretroviral therapy on anaemia and relationship between anaemia and survival in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2004; 37: 1245-52.
6. Lau B, Gange SJ, Phair JP et al. Use of total lymphocyte count and haemoglobin concentration for monitoring progression of HIV infection. J Acquir Immune Defic Syndr 2005; 39: 620-5.
7. Wills T, Nadler J, Somboonwit C et al. Anaemia prevalence and associated risk factors in a single-center ambulatory HIV clinical cohort. AIDS Read 2004; 14: 305-15.
8. Mocroft A, Kirk O, Barton S et al. Anaemia is an independent predictive marker for clinical prognosis HIV-infected patients from across Europe. J Acquir Immune Defic Syndr 1999; 13: 943-50.
9. Curkendall SM, Richardson JT, Emmons MF et al. Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 2007; 8: 483-90.
10. Groopman J. Fatigue in cancer and HIV/AIDS. Oncology (Huntingt) 1998; 12: 335-44.
11. Abrams D, Steinhart C, Frascino R. Epoietin alfa therapy for anaemia in HIV-infected patients: Impact on quality of life. Int J STD AIDS 2000; 11: 659-65.
12. Saag MS, Bowers P, Leitz GJ et al. Once-weekly epoetin alfa improves quality of life and increases haemoglobin in anemic HIV+ patients. AIDS Res Hum Retrovirus 2004; 20: 1037-45.
13. Maynard JL, Guiguet M, Arsac S et al. Frequency and risk factors of infectious complications in neutropenic patient infected with HIV. J Acquir Immune Defic Syndr 1997; 11: 995-8.
14. Richman D, Fischl M, Grieco M et al., for the AZT Collaborative Working Group. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987; 317: 192-7.
15. Koch MA, Volberding PA, Lagakos SW et al. Toxic effects of zidovudine in asymptomatic human immunodeficiency virus-infected individuals with CD4+ cell counts of 0.50 × 109/L or less. Detailed and updated results from protocol 019 of the AIDS clinical trial group. Arch Intern Med 1992; 152: 2286-92.
16. Johnson M, Caiazzo T, Molina JM et al. Inhibition of bone marrow myelopoiesis and erythropoiesis in vitro by anti-retroviral nucleoside derivatives. Br J Haematol 1988; 70: 137-41.
17. Moore R, Forney D. Anaemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29: 54-7.
18. Semba R, Shah N, Klein R et al. Prevalence and cumulative incidence of and risk factors for anaemia in a multicenter cohort study of human immunodeficiency virus-infected and un-infected women. Clin Infect Dis 2002; 34: 260-6.
19. Levine A, Berhane K, Masri-Lavine L et al. Prevalence and correlates of anaemia in a large cohort of HIV-infected women: Women's Interagency HIV study. J Acquir Immune Defic Syndr 2001; 26: 28-35.
20. Gallant J, Dejesus E, Arribas J et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-60.
21. Moh R, Danel C, Sorho S et al. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte d'Ivoire. Antiviral Ther 2005; 10: 615-24.
22. Molina JM, Journot V, Morand-Joubert L at al. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: A randomized trial. J Infect Dis 2005; 191: 830-9.
23. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. MedDRA® term selection: points to consider. http://www.ich.org/cache/compo/276-254-1.html (12 November 2007, date last accessed).
24. Watchel T, Piette J, Mor V et al. Quality of life in persons with human immunodeficiency virus infection: Measurement by the Medical Outcomes Study Instrument. Ann Intern Med 1992; 116: 129-37.
25. Wu AW, Revicki DA, Jacobson D et al. Evidence of reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res 1997; 6: 481-93.
26. Shaunak S, Bartlett JA. Zidovudine-induced neutropenia: Are we too cautious? Lancet 1989; 2: 91-2.
27. Fisher M, Moyle G, Ebrahimi R et al. Switching from Combivir to Truvada maintains viral suppression, prevents and reverse limb fat loss and improves biochemical parameters: Results of a 48 week randomized study. In: Presented at the 11th European AIDS Conference (EACS), Madrid, Spain, 24-27 October 2007. Abstract PS5/7.
28. Moyle GJ, Sabin CA, Cartledge J et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. J Acquir Immune Defic Syndr 2006; 20: 2043-50.